Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of exemestane with or without entinostat in postmenopausal women with ER-positive breast cancer progressing on non-steroidal aromatase inhibitors
2009-012623-28Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of entinostat in breast cancer (2 arms), sponsored by Syndax Pharmaceuticals. Primary endpoint: Progression-free survival. Started Jun 2009; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-012623-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012623-28.